Follow the money

Houston medical device company closes $30 million round

Houston-based Procyrion has closed a $30 million round — doubling its total funding to date. Getty Images

A clinical-stage medical device company based in Houston has rounded up $30 million for its Series D funding. Procyrion Inc.'s round was lead by Bluebird Ventures — a new funding partner for the company.

Procyrion is developing a blood pump, called the Aortix™ system, that's optimized for patients with heart and kidney failure. Joining in on the round with Bluebird are return investors, including Fannin Partners, Scientific Health Development, the State of Texas, and an undisclosed strategic investor. This round has now more than doubled the company's total funding, bringing that figure now to $59 million.

"Of the more than 1 million patients per year in the U.S. admitted to the hospital with acute decompensated heart failure, 25 to 30 percent also have worsening renal function," says Eric S. Fain, president and CEO of the company, in a release. "These are typically the most difficult to treat patients with high mortality and rehospitalization rates."

The funds, Fain says, will go toward advancing the medical device, specifically enhancing the system's ability to decongest cardio renal patients in the company's pilot program.

"Today there is a major gap in effective therapies that are available to treat these critically ill patients, and as such, there is a significant opportunity to improve patient outcomes," Fain continues in the release. "The Aortix device is uniquely designed and positioned in the body to simultaneously decrease the workload of the heart and improve kidney function."

The Aortix device is a solution for patients who haven't seen success from medical therapy, but don't have the immediate need for a transplant or more drastic solution. The device is thinner than a pencil, the release says, and can be inserted in a matter of minutes in a cath-lab setting. The size and ease of application could be transformational for the large population of heart patients that would need it.

In addition to the funds, Jeff Bird, managing director of Bluebird Ventures, will join the company's board of directors.

"The Procyrion Aortix device provides an elegant solution for managing heart failure, a serious and difficult-to-treat problem," says Bird in the release. "We are excited to work with this experienced team as they begin clinical testing."


The device is thinner than a pencil and can be inserted in less than 10 minutes. Photo via procyrion.com

Trending News

Building Houston

 
 

Houston-based NanoTech Inc. has announced it's closed its seed round of funding. Photo courtesy of NanoTech

It's payday for a Houston startup that is housed out of the new Halliburton Labs. Nanotech Inc., which material science for fire-proofing and insulation, has announced the close of its $5 million seed round.

According to NanoTech's news release, Austin-based Ecliptic Capital led the investment round. Additionally, the deal also resulted in the conversion of a simple agreement for future equity, or SAFE, that was previously issued to Halliburton Labs.

"The investment from Ecliptic Capital will allow us to scale our business to achieve our mission of fireproofing the world and reducing global energy consumption. Additionally, our participation with Halliburton Labs provides us with the support of a Fortune 500 company." says NanoTech's CEO Mike Francis in the release.

Based in Austin, Ecliptic Capital is a fund focused on early-stage startups and supports a wide range of technologies across neglected geographies and industries.

"Ecliptic is proud to partner with NanoTech as the company's founding institutional investor," says Mike W. Erwin, founder of Ecliptic Capital, in the release. "We're excited to work with the company and leverage our operational expertise to rapidly scale this impactful, world-changing technology. We look forward to a new world where NanoTech accelerates the thermal management market from science-fiction to science-fact."

Halliburton Company chose NanoTech among a round of contenders to be the first participant of their 12-month program located at their Houston headquarters. Halliburton provides Nanotech with its own office space, access to Halliburton facilities, technical expertise, and an extensive network to accelerate their product to market.

'We are thrilled to see a Halliburton Labs participant secure their first round of financing, and congratulate the Ecliptic and NanoTech teams,' says Scott Gale, Halliburton Labs executive director, in the release. 'We are confident in the path forward as they work towards achieving a clean energy future.'

NanoTech's proprietary technology has the ability to be utilized for various industries — including commercial construction, chemical plants, oil and gas, aviation, utilities and much more — for eco-friendly spray-on insulation and fireproofing.

"As a company, we are just scratching the surface on where our technology will be used and can't wait to see the business scale." adds Mike Francis.

Trending News